Clinical Trial Update: A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the efficacy and safety of Disitamab Vedotin plus tislelizumab with re-TURBT in patients with HER-2-high expression non-m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Medical University Union Hospital | Conditions: NMIBC | Phase 2 | Status: NOT_YET_RECRUITING